---
title: "From Gila Monster Venom to Global Phenomenon: The History of GLP-1s | Northern Frontier Health"
description: "How 40 years of research, an incretin discovery, and a desert lizard led to today's metabolic medications."
lang: en
json-ld:
---

[![Northern Frontier Health](/assets/logo-CVI8ucRN.png)](/)

[Home](/)[About](/about)[Primary Care](/primary-care)[Urgent Care](/urgent-care)[Infectious Disease](/infectious-disease)[Pricing](/pricing)[FAQ](/faq)[Blog](/blog)[Contact](/contact)

Schedule an Appointment[406-299-4905](tel:406-299-4905)

![From Gila Monster Venom to Global Phenomenon: The History of GLP-1s](https://northernfrontierhealth.com/blog-images/glp1-history-gila.jpg)

May 19, 2026 • Northern Frontier Health

# From Gila Monster Venom to Global Phenomenon: The History of GLP-1s

[Back to Blog](/blog)

It is rare to see a class of medication dominate the cultural conversation as rapidly as GLP-1 receptor agonists have. The science behind them is the result of over 40 years of meticulous research, serendipitous discovery, and a surprising detour through the desert.

## The 1980s: Identifying the "Incretin" Effect

Researchers noticed that oral glucose consumption produced a much higher insulin response than intravenous glucose. This suggested something in the gut was signaling the pancreas. They identified two key hormones: GIP and GLP-1.

## The 1990s: The Gila Monster Connection

In 1992, Dr. John Eng identified a peptide called exendin-4 in Gila monster venom. It was structurally similar to human GLP-1 but significantly more stable — remaining active for hours instead of minutes. This was the "Eureka!" moment proving a long-acting version was possible.

## The 2000s: From Diabetes to Weight Loss

The first breakthrough came in 2005 with FDA approval of exenatide, the synthetic version of the Gila monster peptide, initially as a diabetes medication.

### The Serendipitous Observation

During Type 2 diabetes trials, patients reported an unexpected "side effect": weight loss. Researchers realized GLP-1 receptors in the brain influenced the hypothalamus's satiety center.

## The 2020s: The Era of Potency

Newer iterations like semaglutide (2021) and tirzepatide (2022/2023, a dual GIP/GLP-1 agonist) are far more potent with once-weekly dosing. The paradigm has shifted from "treating diabetes" to "treating metabolic disease."

## Looking Forward

The field is exploring oral versions and triple-agonist combinations targeting GLP-1, GIP, and Glucagon receptors simultaneously.

_Disclaimer: This article is for informational purposes only. Always consult a medical professional for personal health advice._

![](/assets/footer-treeline-DvRSxCto.jpg)

![Northern Frontier Health](/assets/logo-CVI8ucRN.png)

Bringing high-quality healthcare to rural communities through telehealth and house calls.

★  Veteran Owned ★ 

#### Quick Links

-   [About Us](/about)
-   [Primary Care](/primary-care)
-   [Urgent Care](/urgent-care)
-   [Infectious Disease](/infectious-disease)
-   [Pricing](/pricing)
-   [FAQ](/faq)
-   [Refund Policy](/refund-policy)
-   [Cancellation Policy](/cancellation-policy)
-   [Membership Refund Policy](/membership-refund-policy)

#### Services

-   Telehealth Visits
-   House Calls
-   Chronic Disease Management
-   Mental Health
-   Medical Weight Loss
-   Chronic Pain Management

#### Contact

-   [406-299-4905](tel:406-299-4905)
-   Fax: 406-299-4906 
-   Lincoln, Sanders & Flathead Counties, Montana 

© 2026 Northern Frontier Health. All rights reserved.

[Terms of Service](/terms-of-service)| [Privacy Policy](/privacy-policy)| [Sitemap](/sitemap.xml)

Marketing Pages: [House Calls](/house-calls)| [Medical Weight Loss](/landing-1)

Northern Frontier Health does not provide emergency medical services. If you are experiencing a medical emergency, call 911.

[![NP Igniter](/assets/npigniter-logo-BVHpBLYv.png)](https://npigniter.com)

We value your privacy

We use cookies to enhance your browsing experience and analyze site traffic. By clicking "Accept," you consent to our use of cookies. See our [Privacy Policy](/privacy-policy) for details.

DeclineAccept